A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Phase 2
70
about 3.9 years
18+
39 sites in AL, AZ, CA +16
About this study
This trial is testing a treatment called EIK1001 when combined with pembrolizumab and chemotherapy for people with advanced lung cancer. The goal is to see if this combination is safe, well-tolerated, and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Carboplatin
- 2.Take EIK1001
- 3.Take Paclitaxel
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carboplatin, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), pemetrexed
injection, intravenous, infusion, injection (Injection)
Secondary: Percentage of participants with objective response rate (ORR) and duration of response (DOR).
Oncology